Cas:5614-78-8 6-Chromanol manufacturer & supplier

We serve Chemical Name:6-Chromanol CAS:5614-78-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

6-Chromanol

Chemical Name:6-Chromanol
CAS.NO:5614-78-8
Synonyms:3,4-dihydrobenzopyran-6-ol;2H-1-Benzopyran-6-ol, 3,4-dihydro-;3,4-dihydro-6-hydroxy-2H-1-benzopyran;chroman-6-ol;6-Chromanol;6-hydroxychromane;2H-1-Benzopyran-6-ol,3,4-dihydro;6-hydroxychroman;6-Hydroxy-3,4-dihydro-2H-benzopyran
Molecular Formula:C9H10O2
Molecular Weight:150.174
HS Code:2932999099

Physical and Chemical Properties:
Melting point:N/A
Boiling point:305.5±31.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.581
PSA:29.46000
Exact Mass:150.068085
LogP:2.07

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3,4-dihydrobenzopyran-6-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Hydroxy-3,4-dihydro-2H-benzopyran physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2H-1-Benzopyran-6-ol, 3,4-dihydro- Use and application,3,4-dihydro-6-hydroxy-2H-1-benzopyran technical grade,usp/ep/jp grade.


Related News: The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said. 6-Chromanol manufacturer At the same time, experts said that API companies need to increase investment in environmental protection, carry out industrial upgrades, improve processes, improve pollution treatment capabilities, and then achieve sustainable development in the future, and seize structural opportunities. 6-Chromanol supplier At the same time, experts said that API companies need to increase investment in environmental protection, carry out industrial upgrades, improve processes, improve pollution treatment capabilities, and then achieve sustainable development in the future, and seize structural opportunities. 6-Chromanol vendor Most of California’s COVID-19 restrictions were lifted on Tuesday and the nation’s most populous state is poised to come roaring back,” according to Gov. Gavin Newsom.
State social distancing rules and capacity limits at restaurants, bars, supermarkets, gyms, stadiums and other locations have been rolled back, and masks will no longer be required for vaccinated people in most settings, the Associated Press reported.
However, businesses and counties can still require them.
In March 2020, California became the first in the United States to impose a statewide shutdown. More people tested positive for the virus (3.8 million to date) and more people died (more than 63,000) in California than anywhere else in the country, but it had a lower per capita death rate than most others, the AP reported.
California now has one of the lowest infection rates (below 1%) in the U.S.
That low rate and a rising number of vaccinated residents — over 70% of adults have had at least one shot — led Newsom to announce in April that most pandemic restrictions would be lifted June 15, the AP reported.
However, the governor has repeatedly said the reopening doesn’t mean the pandemic is over, and some public health measures will still be in place for “mega events. 6-Chromanol factory The Darzalex-Rd regimen got its FDA go-ahead in transplant-ineligible patients in 2019 based on data from the same phase 3 MAIA trial showing it could pare down the risk of disease progression or death by 44% after a median follow-up of 28 months. Now, after 56.2 months of follow-up, over half of Darzalex patients were still alive without their disease worsening, a showing that’s again “unprecedented” for a front-line myeloma treatment, Tendler said.